

- [9] Garibaldi C, Ronchi S, Cremonesi M, Gilardi L, Travaini L, Ferrari M, *et al.* Interim FDG PET/CT during chemoradiation therapy in the management of head and neck cancer patients: a systematic review. *Int J Radiat Oncol Biol Phys* 2017;98:555–573.
- [10] Ang K, Harris J, Wheeler R, Weber R, Rosenthal D, Nguyen-Tan P, *et al.* Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med* 2010;363:24–35.
- [11] Berthon B, Evans M, Marshall C, Palaniappan N, Cole N, Jayaprakasam V, *et al.* Head and neck target delineation using a novel PET automated segmentation algorithm. *Radiother Oncol* 2017;122:242–247.
- [12] Berthon B, Spezi E, Galavis P, Shepherd T, Apte A, Hatt M, *et al.* Toward a standard for the evaluation of PET-auto-segmentation methods following the recommendations of AAPM task group No. 211: Requirements and implementation. *Med Phys* 2017;44(8):4098–4111.

<https://doi.org/10.1016/j.clon.2019.05.005>

© 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Carbon and Cancer

Madam — As over 1000 Extinction Rebellion protesters have recently sought arrest in London, children across the globe are marching out of classrooms to disturb our sleep-walk into catastrophic global warming and the ‘sixth mass extinction’ of our planet gains pace [1,2], it is worth reflecting on the relationship between carbon emissions and cancer.

Oncologists continue to make rapid, though marginal, improvements in the treatment of cancer [3], but unless its underlying causes are tackled, these gains will be offset by epidemiological reality. A World Health Organization report has linked climate change to malignancies of the skin, cornea, conjunctiva and uvea [4]. Ten per cent of cases of lung cancer in the UK are caused by air pollution [5] and, worldwide, there were 223 000 deaths from lung cancer attributed to air pollution in 2010 [6]. Rates of gastrointestinal, breast and bladder cancers rise with increasing emissions from motor vehicles and power stations [7,8]. Carbon emissions will therefore increase the prevalence of cancer, as well as precipitating geopolitical instability, famine and warfare; all of which have obvious public health implications [9,10].

If the oncology community accepts the scientific consensus summarised above and the premise that there still exists a window of opportunity to forestall a ‘tipping point’ [11], it could consider:

- Curtailing the use of air flight as a means of travelling to academic meetings. (Academics are outliers in their disproportionate use of air travel and thereby incur their greatest carbon debt.) [12].
- Embracing initiatives to reduce the carbon footprints of the institutions where cancer care is delivered, e.g. the NHS Carbon Reduction Strategy for England [13].
- Using its influence to advocate for meaningful political change to halt carbon emissions.

Conflicts of interest

None declared.



E. Chandy

UCL Cancer Institute, London, UK

References

- [1] Stuart AJ, Kosintsev PA, Higham TFG, Lister AM. Pleistocene to Holocene extinction dynamics in giant deer and woolly mammoth. *Nature* 2004;431(7009):684–689.
- [2] Sánchez-Bayo F, Wyckhuys KAG. Worldwide decline of the entomofauna: a review of its drivers. *Biol Conserv* 2019;232:8–27.
- [3] Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. *BMJ* 2017;359:j4530.
- [4] World Health Organization. *Climate change and human health* 2019. Available at: <https://www.who.int/globalchange/climate/summary/en/index7.html>; 2019.
- [5] Brown KF, Rungay H, Dunlop C, Ryan M, Quartly F, Cox A, *et al.* The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. *Br J Cancer* 2018;118(8):1130–1141.
- [6] Straif K, Cohen A, Samet J. *Air pollution and cancer*. Geneva: International Agency for Research on Cancer; 2013.
- [7] Royal College of Physicians. *What the RCP thinks about air pollution*. London: Royal College of Physicians; 2018.
- [8] Wong CM, Tsang H, Lai HK, Thomas GN, Lam KB, Chan KP, *et al.* Cancer mortality risks from long-term exposure to ambient fine particle. *Cancer Epidemiol Biomarkers Prevent* 2016;25(5):839–845.
- [9] Watts N, Amann M, Arnell N, Ayeb-Karlsson S, Belesova K, Berry H, *et al.* The 2018 report of the Lancet Countdown on health and climate change: shaping the health of nations for centuries to come. *Lancet* 2018;392(10163):2479–2514.
- [10] Bowles DC, Butler CD, Morisetti N. Climate change, conflict and health. *J R Soc Med* 2015;108(10):390–395.
- [11] Hoegh-Guldberg O, Jacob D, Taylor M, Bindi M, Brown S, Camilloni I, *et al.* Impacts of 1.5°C Global Warming on Natural and Human Systems. In: Masson-Delmotte V, Zhai P, Pörtner H-O, Roberts D, Skea J, Shukla PR, *et al.*, editors. *Global Warming of 1.5°C. An IPCC Special Report on the impacts of global warming of 1.5°C above pre-industrial levels and related global greenhouse gas emission pathways, in the context of strengthening the global*

response to the threat of climate change, sustainable development, and efforts to eradicate poverty 2018. In Press.

- [12] Nevins J. Academic jet-setting in a time of climate destabilization: ecological privilege and professional geographic travel. *Prof Geogr* 2014;66(2):298–310.

- [13] Sustainable Development Unit. *Carbon reduction strategy* 2009. Available at: <https://www.sduhealth.org.uk/policy-strategy/engagement-resources/nhs-carbon-reduction-strategy-2009.aspx>; 2009.

<https://doi.org/10.1016/j.clon.2019.05.006>

Crown Copyright © 2019 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. All rights reserved.

Mode of Histological Diagnosis in Patients With Non-small Cell Lung Cancer Treated With Chemoradiotherapy: Its Prognostic Implication, Especially in Light of the European Durvalumab Licence?



Madam – Chemoradiotherapy is the standard of care in locally advanced non-small cell lung cancer. The PACIFIC trial showed that durvalumab after chemoradiotherapy was associated with a significant survival benefit [1]. However, the European Medicines Agency restricted durvalumab approval to patients with PDL1-positive tumours [2]. Experts criticised this restriction as it was based on an unplanned *post-hoc* analysis [3].

We recently published the outcomes of 100 patients treated with hypofractionated chemoradiotherapy [4] and assessed mechanisms of histological/cytological diagnosis and its prognostic associations as posited by Peters *et al.* [3]. We found that 82% of patients were diagnosed on the first procedure; 21 patients required at least one more procedure to obtain tissue or complete staging. Fifty-one per cent of patients had successful biopsies by bronchoscopy, but 34% were diagnosed on brushes or lavages, which are unlikely to allow PDL1 testing and would not be suitable for analysis within a clinical trial such as PACIFIC (where 15–20 slides or a block of histological sample were required) [1].

We therefore assessed the prognostic impact for patients who were unable to supply an acceptable tissue sample within PACIFIC compared with the rest of the cohort. We found that there was no impact on progression-free survival (median 577 days versus 475 days; $P = 0.52$) or overall survival (median 1224 days versus 1510 days; $P = 0.60$). We were intrigued by the suggestion of a difference in post-progression survival (median 484 days versus 223 days; $P = 0.05$). The reason for this difference is unclear; all patients were treated before the routine use of immunotherapies within the National Health Service.

Although not an end point in PACIFIC, post-progression survival is an important component of health economic models developed to assess the potential cost-effectiveness of new therapies, such as durvalumab. Our data show the potential impact of carrying out a *post-hoc* analysis only in patients with evaluable biomarkers, as there may be subtle differences due to a bias selection of patients. Our analysis

supports the assertion of Peters *et al.* [3] that there can be an unintentional introduction of potential bias when this is carried out.

Conflict of interest

The authors declare no conflict of interest.

M.S. Iqbal*, E. Smith*, M. Cunnell†, A. Greystoke†

* Department of Clinical Oncology, Northern Centre for Cancer Care, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

† Department of Medical Oncology, Northern Centre for Cancer Care, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

References

- [1] Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, *et al.* Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *N Engl J Med* 2018;379(24):2342–2350. <https://doi.org/10.1056/NEJMoa1809697>. PubMed PMID: 30280658.
- [2] <https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi>. [Accessed 13 March 2019]
- [3] Peters S, Dafni U, Boyer M, De Ruyscher D, Faivre-Finn C, Felip E, *et al.* Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). *Ann Oncol* 2019;30:161–165. <https://doi.org/10.1093/annonc/mdy553>. PubMed PMID: 30624547.
- [4] Iqbal MS, Vashisht G, McMenemin R, Atherton P, McDonald F, Simmons T, *et al.* Hypofractionated concomitant chemoradiation in inoperable locally advanced non-small cell lung cancer: a report on 100 patients and a systematic review. *Clin Oncol* 2019;31(2):e1–e10. <https://doi.org/10.1016/j.clon.2018.10.006>. PubMed PMID: 30415784.

<https://doi.org/10.1016/j.clon.2019.06.006>

Crown Copyright © 2019 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. All rights reserved.